期刊
JOURNAL OF THE NEUROLOGICAL SCIENCES
卷 274, 期 1-2, 页码 39-41出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2008.03.022
关键词
Antigen presentation; Brain; Crohn's disease; Immunosuppression; Inflammatory bowel disease; Integrin; JC virus; Natalizumab; Perivascular spaces; Pharmacotherapy; PML; Polyoma virus; Progressive multifocal leukoencephalopathy; Tysabri; Virchow Robin space
Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the central nervous system (CNS). Natalizumab ((R) Tysabri) is a humanized recombinant monoclonal antibody that binds to the alpha (alpha)(4) chain of the alpha(4) beta (beta)(1) integrin (very late activation antigen 4; VLA-4), and alpha(4)beta(7) integrin. Recently, two patients with MS and one patient with Crohn's disease who were treated with natalizumab in the setting of clinical trials developed progressive multifocal leukoencephalopathy (PML), an opportunistic infection of the brain with the polyoma virus JC. We recently showed that natalizumab decreases the numbers of CD4(+) and CD8(+) T lymphocytes, CD19(+) B cells, and CD138(+) plasma cells in the cerebrospinal fluid (CSF) of patients with MS on natalizumab therapy. In addition, we demonstrated that the cell numbers in CSF remained unchanged even 6 months after cessation of natalizumab treatment. Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据